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Original Article
Rethinking Undertreatment in Elderly 
Breast Cancer Patients
Melanie DW Seah and Patrick MY Chan, Breast Service, Department of General Surgery,
Tan Tock Seng Hospital, Singapore.
In treating the elderly breast cancer patient, there are proponents for both conservative as well as stan-
dard treatment. With this background, we aim to determine the impact of undertreatment on recurrence
and propose a surgical management plan. Data of patients 70 years old and above were collected from a
prospectively maintained database. Of 165 patients in this study period, surgery was performed for 132
patients. In this group, 63 cases were undertreated by conventional definitions. Locoregional recurrence
(LRR) occurred in three patients while four patients had metastatic recurrence. There was no significant
difference in LRR or metastatic recurrence for both the undertreated and adequately treated groups.
However, patients who had inadequate locoregional treatment were more likely to have locoregional
recurrence. We conclude that standard locoregional treatment should be offered to these patients as the
procedures are low risk in nature and will provide better loco-regional control of the disease. [Asian J Surg
2009;32(2):71–5]
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Introduction
‘How far should one go?’ is always the question to consider
when treating an elderly patient with breast cancer. Various
studies that advocate conservative treatment cite acceptable
regional relapse rates1–5 and similar survival rates between
those undertreated and those not.6–10
There is also the belief that breast cancer in this age
group behaves in an indolent manner and elderly patients
are more likely to succumb from other conditions rather
than the cancer itself. In addition to this, elderly patients
are higher risk surgical candidates compared to younger
patients. Nevertheless, there are alternative results that
continue to lend support for standard therapy in elderly
patients.11–14
There are the few patients who will be deemed unfit or
high risk candidates for surgical intervention or those who
will decline intervention altogether. In the majority how-
ever, intervention is possible and it is with this group of
patients where addressing the above question becomes
important. With this in mind we wanted to determine if
undertreatment in this specific group of elderly patients
impacts disease recurrence.
Patients and methods
Case records of women from January 2001 to May 2005
with the diagnosis of breast cancer, were reviewed. Data was
obtained from a prospectively maintained database. Patients
were stratified to those who had no surgery and those who
had underwent surgery. For the group of interest—the
patients who did undergo surgery, undertreatment was
defined by four criteria. The first criterion was inadequate
axillary treatment for patients who had an invasive tumour.
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Adequate axillary treatment in this context comprised either
an axillary clearance or a histologically negative axillary
sampling or sentinel lymph node biopsy. A positive 
axillary sampling or sentinel lymph node biopsy would
necessitate complete axillary clearance.
The subsequent criteria were the omission of radio-
therapy to the breast after breast conserving surgery, the
omission of chemotherapy in tumours staged T2 and
above or those with lymph node positive tumours, as well
as the omission of hormonal therapy in patients whose
tumours are oestrogen receptor positive. Any patient who
fulfilled any one of the above criteria was considered under-
treated for the purposes of the study. The characteristics
and recurrence rates of this undertreated group was com-
pared with those who completed standard treatment.
In addition, this group of patients was stratified into
those who completed standard locoregional therapy and
those who did not. Locoregional undertreatment was
defined solely by the omission of an axillary clearance in
invasive tumours and the omission of radiotherapy to the
breast after breast conserving surgery. The impact of loco-
regional undertreatment on locoregional recurrence was
examined. Chi-square statistics was used for comparisons.
Results
There were 162 patients aged 70 years old and above, in this
four years and five months study period who were diag-
nosed with breast cancer. Three (2%) of the patients had
bilateral breast cancer giving a total of 165 cancers diagnosed
within the study period. The mean age at diagnosis was 77.4
years (range, 70–94 years). There were 143 Chinese (88%),
nine Malay (6%), nine Indian (6%) and one Eurasian (1%).
Surgery was performed for 132 cases (80%). Of the 33
patients (20%) who did not undergo surgery, 10 had
advanced disease, 10 refused surgery, six were deemed unfit
for surgery, five defaulted on follow-up, one died before the
scheduled surgery and one refused all forms of treatment.
Following the group of 132 cases that underwent sur-
gery, mastectomies were performed for 87 tumours while
wide excisions were performed for 45 other tumours.
Axillary clearance was performed in 105 cases. One patient
had axillary sampling performed while another two had
sentinel lymph node biopsy performed.
Post surgery, 32 patients had chemotherapy and radio-
therapy was administered in 56 cases. Tamoxifen was
started in 80 patients.
Of the 132 cases that underwent surgery, 63 (48%) were
still undertreated by our criteria. Nineteen were invasive car-
cinomas with no axillary clearance done, 13 did not receive
radiotherapy to the breast after a wide excision while 10
which were ER positive did not receive tamoxifen. There
were 24 that were lymph node positive who did not receive
chemotherapy. There were also 42 that were at least T2
tumours who did not receive chemotherapy.
These undertreated patients were older (Table 1). They
were also more likely to have larger tumours, the majority
of these lesions being T2, compared to patients who were
adequately treated, who had mostly T1 lesions (Table 1).
Reasons given for undertreatment were that of advanced
age and multiple comorbidities (47 cases, 75%), patient
refusal (15 cases, 24%) and default in further follow-up 
(one case, 1%).
Locoregional recurrence (LRR) occurred in three
patients (2% of patients who had surgery). The mean time
to recurrence was 24.0 months from the time of the first
surgery. The site of LRR was at the chest wall in one patient,
and the axilla in two patients.
Four patients had metastatic recurrence (3% of patients
who had surgery). One patient had liver metastases with
concurrent axillary recurrence while another had both liver
and lung metastases. One patient each had isolated bone
and liver metastatic recurrence. The time to metastatic
recurrence from first surgery was 14.6 months.
Locoregional undertreatment was defined as omission
of axillary clearance in invasive cancers and the omission of
radiotherapy to the chest wall in breast conserving surgery.
Using this criterion, 21 cases (16%) had inadequate loco-
regional treatment. We found that there is a significantly
higher rate of locoregional recurrence in patients with inad-
equate locoregional treatment (Table 2). Subsequent analy-
sis that excluded patients who had T4, N3 or M1 disease
also yielded similar results.
Overall, 11 patients passed away during the study
period. Eight died from metastatic breast cancer and the
remaining three from non breast cancer related causes. Ten
of these deaths belonged to the group who did not have any
surgery performed at all (30%). The mean follow up period
was 24 months (range, 0–53 months).
Discussion
The treatment trends in our cohort of elderly breast cancer
patients are not unexpected. Undertreatment is common
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as with other cohorts around the globe.1,8–12,15–17 A rather
high percentage (20%) of our patients did not undergo
surgery at all. These were mainly those whose disease was
very advanced, those who refused outright and those who
were not fit for surgery. From this poor prognosis group,
30% died during the study period.
Of the eventual 132 cases that were operated on, only 69
completed adequate treatment by conventional standards.
Table 1 details the differences between the under treated
and adequately treated patients. Omission of chemother-
apy is the prime reason why most patients fall into the
under treated category in the first place. Advanced age
and multiple comorbidities is the reason for under treat-
ment in almost three quarters of these cases and our series
does reveal that the under treated patients are likely to be
older. Omission of chemotherapy is not unexpected as the
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Table 1. Comparing undertreated and adequately treated patients
Undertreated Adequately treated p value
n 63 69
Mean age (yrs) 78.35 75.1 0.001
Surgery
Breast conservation 27 (43%) 18 (26%) 0.046
Mastectomy 36 (57%) 51 (74%)
Axillary clearance 44 (70%) 61 (88%) 0.01
Histopathology
Infiltrating ductal 63 (100%) 55 (80%) <0.001
Ductal carcinoma in situ 0 (0%) 14 (20%)
Tumour stage
pTis 0 (0%) 14 (20%) <0.001
pT1 18 (29%) 31 (45%)
pT2 36 (57%) 19 (28%)
pT3 2 (3%) 3 (4%)
pT4 7 (11%) 2 (3%)
Involved nodes
pN0 38 (60%) 48 (70%) 0.214
pN1 16 (25%) 10 (15%)
pN2 7 (11%) 5 (7%)
pN3 2 (3%) 6 (9%)
Metastatic disease at presentation
M0 51 (81%) 45 (65%) 0.062
M1 0 (0%) 1 (1%)
Not assessed 12 (19%) 23 (33%)
Estrogen receptor positive 44 (72%) 39 (68%) 0.691
Progesterone receptor positive 34 (56%) 27 (47%) 0.461
Adjuvant chemotherapy 3 (5%) 29 (42%) <0.001
Adjuvant radiotherapy 24 (38%) 32 (46%) 0.38
Tamoxifen 36 (57%) 44 (64%) 0.479
Recurrence
LRR recurrence 3 (5%) 0 (0%) 0.106
Systemic recurrence 2 (3%) 2 (3%) 0.655
Death 0 (0%) 1 (1%) 1
LRR = locoregional recurrence.
side effects of the agents are not well tolerated, particu-
larly in candidates with poor cardiac risk.
The omission of axillary clearance is another qualify-
ing factor for under treatment and this accounts for this
difference between the two groups. The higher numbers
of breast conserving surgery in the under treated group
can be accounted in small part by a few cases where sur-
gery was performed under local anaesthesia. In these
patients also, an axillary clearance was omitted.
Breaking down the numbers according to locoregional
treatment, the fraction of patients who received inade-
quate locoregional therapy was small (16%) (Table 2).
However, all the locoregional recurrences came from this
group. This was statistically significant compared to
patients who had adequate locoregional therapy. This
reinforces the importance of adequate locoregional therapy
in the prevention of local recurrences. In practice, this is
feasible as most of these patients are already under general
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Table 2. Comparing patients based on adequacy of locoregional treatment
Inadequate locoregional Adequate locoregional 
p value
treatment treatment
n 21 (16%) 111 (84%)
Mean age (yrs) 81.86 75.67 <0.001
Surgery
Breast conservation 19 (95%) 29 (26%) <0.001
Mastectomy 1 (5%) 82 (74%)
Axillary clearance 2 (10%) 103 (93%) NA
Histopathology
Infiltrating ductal 21 (100%) 97 (87%) 0.125
Ductal carcinoma in situ 0 (0%) 14 (13%)
Tumour stage
pTis 0 (0%) 14 (13%) 0.798
pT1 9 (43%) 40 (36%)
pT2 9 (43%) 46 (41%)
pT3 0 (0%) 5 (5%)
pT4 3 (14%) 6 (5%)
Involved nodes
pN0 20 (95%) 66 (59%) NA
pN1 1 (5%) 25 (23%)
pN2 0 (0%) 12 (11%)
pN3 0 (0%) 8 (7%)
Metastatic disease at presentation
M0 14 (67%) 82 (74%) NA
M1 0 (0%) 1 (1%)
Not assessed 7 (33%) 28 (25%)
Estrogen receptor positive 15 (71%) 68 (61%) 0.656
Progesterone receptor positive 10 (48%) 51 (46%) 0.981
Adjuvant chemotherapy 2 (10%) 30 (27%) 0.102
Adjuvant radiotherapy 8 (38%) 48 (43%) 0.811
Tamoxifen 14 (67%) 66 (59%) 0.63
Recurrence
LRR recurrence 3 (14%) 0 (0%) 0.004
Systemic recurrence 3 (14%) 4 (4%) 0.08
Death 0 (0%) 1 (1%) NA
LRR = locoregional recurrence.
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anaesthesia for the breast surgery and the addition of sur-
gery to the axilla can be done within reasonable time lim-
its without adding too much to the patient’s surgical risk.
The same reasoning can be applied where radiotherapy to
the chest wall after a wide excision, is concerned. The side
effects of radiotherapy are mostly local and with precise
planning to avoid excessive radiation to the heart, it can
be performed safely even in the context of advanced age
and multiple comorbidities.
In the interest of avoiding a second surgical procedure
in an elderly patient, it would seem logical then that 
the minimum treatment when the patient consents and
is fit, should include clearance of the primary tumour and
axilla where appropriate, as well as radiotherapy when
breast conservation methods are employed.
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